Organization Overview
Historical Acquisition Tree
Alternative names
niraparib (zejula) (2017 NDA)
rolapitant (varubi) (2015 NDA)
atezolizumab (tecentriq) (1 trial)
bevacizumab (avastin) (3 trials)
cabozantinib (cometriq) (1 trial)
enfortumab vedotin (Padcev) (1 trial)
fluorouracil (efudex) (1 trial)
Isatuximab (Sarclisa) (1 trial)
Adenocarcinoma (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Ovarian Epithelial (Phase 4)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Carcinosarcoma (Phase 3)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Cystadenocarcinoma, Serous (Phase 2)
Endometrial Neoplasms (Phase 3)
Fallopian Tube Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hypersensitivity (Phase 3)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Prolymphocytic (Phase 1)
Leukemia, Prolymphocytic, T-Cell (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Mixed Tumor, Mullerian (Phase 3)
Nausea (Phase 3)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Ovarian Neoplasms (Phase 4)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Rectal Neoplasms (Phase 2)
Sarcoma (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vomiting (Phase 3)